Markets:

Overview

News

Currencies

International

Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

16.35 +0.86 (+5.54%)

Streaming Delayed Price Updated: 2:53 PM EDT, Mar 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Spyre Therapeutics focuses on antibody therapies for inflammatory bowel disease, advancing a pipeline aimed at gastrointestinal health.

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

This ophthalmic biopharma firm develops sustained drug delivery therapies for eye diseases, targeting both U.S. and global markets.

Via The Motley Fool

Topics Regulatory Compliance

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.

Via The Motley Fool

Topics Regulatory Compliance

KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year ↗

September 19, 2025

Via Stocktwits

KalVista Pharma's Earnings: A Preview ↗

September 10, 2025

Via Benzinga

Recap: KalVista Pharma Q3 Earnings ↗

March 11, 2024

Via Benzinga

KalVista Pharmaceuticals Stock Rallies After Hours On Strong Genetic Disorder Drug Sales Kickstart ↗

January 08, 2026

Ekterly is the first and only oral on-demand treatment for HAE, KalVista said, setting it apart from other on-demand HAE treatment options approved in the U.S.

Via Stocktwits

Get insights into the top gainers and losers of Thursday's after-hours session. ↗

January 08, 2026

Via Chartmill

These stocks are moving in today's session ↗

December 03, 2025

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Via Chartmill

Examining the Future: KalVista Pharma's Earnings Outlook ↗

November 10, 2025

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

September 24, 2025

Via Benzinga

KalVista Posts 154% Expense Jump in Q1 ↗

September 11, 2025

Via The Motley Fool

KalVista Pharmaceuticals Inc (NASDAQ:KALV) Stock Rises 7.4% on Strong EKTERLY Launch Despite Q1 Earnings Miss ↗

September 11, 2025

KalVista stock rises 7.4% on strong EKTERLY launch, despite Q1 revenue miss and wider EPS loss. Early HAE treatment adoption exceeds expectations.

Via Chartmill

Earnings Scheduled For September 11, 2025 ↗

September 11, 2025

Via Benzinga

KalVista Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗

September 10, 2025

Via Benzinga

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder ↗

August 21, 2025

FDA approved Ionis' Dawnzera for hereditary angioedema, showing up to 87% attack reduction and strong results in switch patients.

Via Benzinga

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

July 14, 2025

Via Benzinga

Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

July 08, 2025

Via Benzinga

KalVista Pharmaceuticals, Cogent Biosciences, WNS And Other Big Stocks Moving Higher On Monday ↗

July 07, 2025

Via Benzinga

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated ↗

July 07, 2025

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous...

Via Stocktwits

KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment ↗

July 07, 2025

The FDA signed off on KalVista Pharmaceuticals' emergency treatment for swelling attacks associated with a rare disease.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 07, 2025

Via Benzinga

FDA Approves KalVista's Ekterly As First Oral On-Demand Treatment For Rare Swelling Disease ↗

July 07, 2025

KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.

Via Benzinga

How KalVista Pharma Is Taking On A Rare But Deadly Disease ↗

June 20, 2025

The company is working on the first new on-demand treatment for hereditary angioedema in 11 years.

Via Investor's Business Daily

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 24, 2024

Via Benzinga

This Box Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

December 18, 2024

Via Benzinga

Super Micro Computer And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 16, 2024

Via Benzinga

NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday ↗

July 12, 2024

Via Benzinga

KALV Stock Earnings: KalVista Pharma Misses EPS for Q4 2024 ↗

July 11, 2024

KALV stock results show that KalVista Pharma missed analyst estimates for earnings per share the fourth quarter of 2024.

Via InvestorPlace

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.